# US 2026/0077042 A1 · Methods of treating psoriatic arthritis using il-17 antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077042 A1
- Document ID: US20260077042A1
- Status: Published application
- Kind: A1
- Application number: 19/389,528
- Filed: 2025-11-14
- Published: 2026-03-19
- Earliest claimed: 2010-11-05
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Shephard MPOFU; Hanno RICHARDS; Karthinathan THANGAVELU; Matthias MACHACEK
- Web page: https://patentgrep.com/patent/US20260077042A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/244: {Interleukins [IL]}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).

## Claims

### Claim 1

A method of treating ankylosing spondylitis in a patient, comprising subcutaneously administering about 150 mg secukinumab to the patient every 4 weeks in a composition comprising:
a) 150 mg/mL secukinumab;
b) a sugar;
c) a surfactant selected from polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80; and
d) water;
wherein the composition has a pH of about 5.5 to about 7.4.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sugar is sucrose, trehalose, raffinose, maltose, sorbitol, or mannitol.

### Claim 3 (depends on 2)

The method of claim 2, wherein the sugar is sorbitol.

### Claim 4 (depends on 2)

The method of claim 2, wherein the sugar is trehalose.

### Claim 5 (depends on 2)

The method of claim 2, wherein the trehalose is at a concentration of about 175 mM to about 300 mM.

### Claim 6 (depends on 1)

The method of claim 1, wherein the surfactant is at a concentration of about 0.01% to about 0.1%.

### Claim 7 (depends on 5)

The method of claim 5, wherein the surfactant is polysorbate 80.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition further comprises a citrate buffer, a phosphate buffer, a succinate buffer, an acetate buffer, or a Tris buffer.

### Claim 9

A method of treating psoriatic arthritis in a patient, comprising subcutaneously administering about 150 mg secukinumab to the patient every 4 weeks in a composition comprising:
a) 150 mg/mL secukinumab;
b) a sugar;
c) a surfactant selected from polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80; and
d) water;
wherein the composition has a pH of about 5.5 to about 7.4.

### Claim 10 (depends on 9)

The method of claim 9, wherein the sugar is sucrose, trehalose, raffinose, maltose, sorbitol, or mannitol.

### Claim 11 (depends on 10)

The method of claim 10, wherein the sugar is sorbitol.

### Claim 12 (depends on 11)

The method of claim 11, wherein the sugar is trehalose.

### Claim 13 (depends on 12)

The method of claim 12, wherein the trehalose is at a concentration of about 175 mM to about 300 mM.

### Claim 14 (depends on 9)

The method of claim 9, wherein the surfactant is at a concentration of about 0.01% to about 0.1%.

### Claim 15 (depends on 14)

The method of claim 14, wherein the surfactant is polysorbate 80.

### Claim 16 (depends on 9)

The method of claim 9, wherein the composition further comprises a citrate buffer, a phosphate buffer, a succinate buffer, an acetate buffer, or a Tris buffer.

### Claim 17

A method of treating ankylosing spondylitis in a patient, comprising subcutaneously administering about 150 mg secukinumab to the patient every 4 weeks in a composition comprising:
a) 150 mg/mL secukinumab;
b) a stabilizer selected from sucrose, mannitol, glycine, arginine, or a combination thereof;
c) a surfactant selected from polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80; and
d) water;
wherein the composition has a pH of about 5.5 to about 7.4; and
wherein the composition is administered every 4 weeks.

### Claim 18 (depends on 17)

The method of claim 17, wherein the composition comprises at least one sugar.

### Claim 19 (depends on 18)

The method of claim 18, wherein the at least one sugar is sucrose, trehalose, raffinose, maltose, sorbitol, or mannitol.

### Claim 20 (depends on 19)

The method of claim 19, wherein the at least one sugar is trehalose.

### Claim 21 (depends on 17)

The method of claim 17, wherein the surfactant is at a concentration of about 0.01% to about 0.1%.

### Claim 22 (depends on 21)

The method of claim 21, wherein the surfactant is polysorbate 80.

### Claim 23 (depends on 17)

The method of claim 17, wherein the composition further comprises a citrate buffer, a phosphate buffer, a succinate buffer, an acetate buffer, or a Tris buffer.

### Claim 24

A method of treating psoriatic arthritis in a patient, comprising subcutaneously administering about 150 mg secukinumab to the patient every 4 weeks in a composition comprising:
a) 150 mg/mL secukinumab;
b) a stabilizer selected from sucrose, mannitol, glycine, arginine, or a combination thereof;
c) a surfactant selected from polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80; and
d) water;
wherein the composition has a pH of about 5.5 to about 7.4.

### Claim 25 (depends on 24)

The method of claim 24, wherein the composition comprises at least one sugar.

### Claim 26 (depends on 25)

The method of claim 25, wherein the at least one sugar is sucrose, trehalose, raffinose, maltose, sorbitol, or mannitol.

### Claim 27 (depends on 26)

The method of claim 26, wherein the at least one sugar is trehalose.

### Claim 28 (depends on 24)

The method of claim 24, wherein the surfactant is at a concentration of about 0.01% to about 0.1%.

### Claim 29 (depends on 28)

The method of claim 28, wherein the surfactant is polysorbate 80.

### Claim 30 (depends on 24)

The method of claim 24, wherein the composition further comprises a citrate buffer, a phosphate buffer, a succinate buffer, an acetate buffer, or a Tris buffer.
